CombiGene’s CEO gives business development update

CombiGene’s pilot study, which is aimed at optimising the administration of the drug candidate CG01, has given the company valuable insights for future development steps. The path towards clinical studies, which will take place with support from partner Spark Therapeutics, thus takes another step forward. BioStock contacted the company’s CEO Jan Nilsson who talks about the collaboration with Spark, and how the company views its intensified investment in business development.